Personalized, bio-engineered, dermo-epidermal skin grafts.
CUTISS is a Swiss clinical-stage life sciences company focussed on skin regenerative medicine and tissue engineering. It is developing the first personalised and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries.
The lead product denovoSkin promises to take skin surgery to the next level and revolutionise current treatments. It is a bio-engineered and personalised dermo-epidermal human skin graft, currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.
CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. The company’s knowledge in skin bio-engineering and biology offers several growth opportunities in regenerative medicine.
Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children’s Hospital and a member of the accelerator Wyss Zurich.
Headquartered at the Bio-Technopark in Zurich, it won the Top 100 Swiss Startup Award 2020, and has raised about CHF 50 million from private investors, family offices and public bodies.
CUTISS is a Swiss clinical-stage life sciences company focussed on skin regenerative medicine and tissue engineering. It is developing the first personalised and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries.
The lead product denovoSkin promises to take skin surgery to the next level and revolutionise current treatments. It is a bio-engineered and personalised dermo-epidermal human skin graft, currently in Phase IIb clinical trials in Switzerland and the European Union, with Orphan Drug Designation for the treatment of burns from Swissmedic, EMA, and FDA.
CUTISS is also developing the world’s first machine that can automate the entire production process of the personalised skin graft. The company’s knowledge in skin bio-engineering and biology offers several growth opportunities in regenerative medicine.
Established in 2017, the company is a spin-off from University of Zurich (UZH) / University Children’s Hospital and a member of the accelerator Wyss Zurich.
Headquartered at the Bio-Technopark in Zurich, it won the Top 100 Swiss Startup Award 2020, and has raised about CHF 50 million from private investors, family offices and public bodies.
Location: Switzerland, Zurich, Kempten
Employees: 11-50
Phone: +41 43 549 21 10
Total raised: $68.34M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | VentureLab | venturelab... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 21.05.2024 | Series C | $27.51M | - |
| 26.01.2022 | - | $338.49K | Venture Ki... |
| 29.06.2020 | Series B | $21.05M | - |
| 05.06.2020 | - | $19.43M | - |
Mentions in press and media 45
| Date | Title | Description |
| 09.07.2024 | CUTISS reports positive Phase 2 results for reconstructive skin surgery | Following the successful completion of the phase I clinical trial, denovoSkin is further evaluated for its safety and efficacy in three parallel phase II clinical trials. These trials are very similar in their design, but differ in the pat... |
| 21.05.2024 | CUTISS secures CHF 25 million in Series C Funding and advances to Phase 3 clinical trials | CUTISS secures CHF 25 million in Series C Funding and advances to Phase 3 clinical trials 21.05.2024 14:00, Rita Longobardi linkedIn facebook twitter instagram youtube --> Leading Biotech startup CUTISS, at the forefront of skin regenera... |
| 21.05.2024 | CUTISS attracts CHF 25 million and enters Phase 3 clinical trials | CUTISS develops the first-in-class personalized and automated skin tissue therapy offering life-saving and life-changing medical treatments for patients with severe skin injuries globally. This first closing allows CUTISS to enter Phase 3 ... |
| 16.05.2024 | CUTISS skintech offers life changing hope for burn victims | Today, I'm writing about a piece of tech that hits close to home. Back in Australia, when my mother was a child, she was severely burned in a kitchen accident from the knee down, resulting in not only severe pain but a lifetime of operation... |
| 29.11.2023 | Swiss medtech startups enter next development phase | |
| 19.05.2023 | Cash and honorary awards for Swiss innovators | |
| 28.04.2023 | Swiss Accelerator: Innosuisse supports 53 companies with CHF112 million | |
| 03.04.2023 | Positive from CUTISS’ Phase I and Phase II clinical studies | |
| 18.03.2023 | Cutiss has skin in the space game with new study on the International Space Station | This week saw the launch of a skin cell study head into space. The research mission saw a SpacePharma micro-lab, containing an experiment by Cutiss, travel to the ISS on SpaceX’s 27th commercial resupply mission (CRS-27) for NASA. Swiss lif... |
| 08.09.2022 | The TOP 100 Swiss Startup Award 2022 celebrates Switzerland’s most promising startups |
Show more